抗 PD-1 抗体在既往接受抗 PD-L1 抗体治疗的非小细胞肺癌患者中的再治疗。
Retreatment with anti-PD-1 antibody in non-small cell lung cancer patients previously treated with anti-PD-L1 antibody.
机构信息
Division of Respiratory Medicine, Center for Respiratory Diseases, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.
Department of Drug Discovery for Lung Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
出版信息
Thorac Cancer. 2020 Jan;11(1):15-18. doi: 10.1111/1759-7714.13241. Epub 2019 Nov 7.
BACKGROUND
This study evaluated the efficacy and safety of retreatment with anti-programmed death 1 (anti-PD-1) antibodies in patients with advanced non-small cell lung cancer (NSCLC) after prior treatment with anti-programmed death-ligand 1 (anti-PD-L1) antibodies.
METHODS
Data (N = 15) on patients' characteristics, number of cycles, regimens, their best response and immune-related adverse events (irAEs) were recorded retrospectively.
RESULTS
NSCLC was initially treated with anti-PD-L1 antibody atezolizumab (N = 14) or durvalumab (N = 1). No patients had a high (≥50%) tumor expression of PD-L1. The median cycles for atezolizumab were five (range 1-15), and median progression-free survival was 2.8 and 6.0 months for atezolizumab and durvalumab, respectively. Five (33.3%) and nine (60.0%) patients showed stable and progressive disease as their best response, respectively. No differences in irAEs between anti-PD-L1 and anti-PD-1 antibodies occurred.
CONCLUSION
Patients treated with anti-PD-L1 antibodies for NSCLC received limited benefits from retreatment with anti-PD-1 antibodies.
背景
本研究评估了既往接受抗程序性死亡配体 1（anti-PD-L1）抗体治疗的晚期非小细胞肺癌（NSCLC）患者，再次使用抗程序性死亡 1（anti-PD-1）抗体的疗效和安全性。
方法
回顾性记录了患者特征、周期数、方案、最佳缓解情况和免疫相关不良事件（irAEs）的数据（N=15）。
结果
NSCLC 最初接受了抗 PD-L1 抗体阿替利珠单抗（N=14）或度伐利尤单抗（N=1）治疗。没有患者的 PD-L1 高表达（≥50%）。阿替利珠单抗的中位周期为 5 个（范围 1-15），阿替利珠单抗和度伐利尤单抗的中位无进展生存期分别为 2.8 和 6.0 个月。最佳缓解分别为 5 名（33.3%）和 9 名（60.0%）患者稳定和进展性疾病。抗 PD-L1 和抗 PD-1 抗体的 irAEs 无差异。
结论
接受抗 PD-L1 抗体治疗的 NSCLC 患者，再次使用抗 PD-1 抗体获益有限。
Zotero 插件